|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||154.53 - 155.86|
|52 Week Range||95.02 - 155.86|
|Beta (5Y Monthly)||0.33|
|PE Ratio (TTM)||53.16|
|Forward Dividend & Yield||1.77 (1.27%)|
|Ex-Dividend Date||Mar 24, 2023|
|1y Target Est||140.39|
Novo Nordisk (NVO) announces positive top-line results from its phase III increased dosage study of semaglutide, 25 mg and 50 mg, for the treatment of patients with type II diabetes.
Bagsværd, Denmark, 27 March 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 28 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme i
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.